Status:
COMPLETED
Misoprostol for the Treatment of Postpartum Hemorrhage
Lead Sponsor:
Gynuity Health Projects
Collaborating Sponsors:
Family Care International
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
Phase:
NA
Brief Summary
The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1)...
Detailed Description
Postpartum hemorrhage (PPH) remains a major cause of maternal deaths worldwide. Misoprostol offers several advantages over oxytocin and ergometrine, the drugs currently used to treat PPH. For example,...
Eligibility Criteria
Inclusion
- Vaginal delivery
- Postpartum hemorrhage due to suspected uterine atony
- Depending on study group: administration of prophylactic uterotonics in third stage of labor
Exclusion
- Known allergy to misoprostol or other prostaglandin
- C-section for current delivery
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
1786 Patients enrolled
Trial Details
Trial ID
NCT00116350
Start Date
July 1 2005
End Date
January 1 2008
Last Update
March 19 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire Souro Sanou de Bobo Dioulasso
Bobo Diolasso, Burkina Faso
2
Hospital Gineco-Obstetrico Isidro Ayora
Quito, Ecuador
3
Alexandria University Hospital, Shatby Maternity Hospital
Alexandria, Egypt
4
El-Galaa Teaching Hospital
Cairo, Egypt